Pharmexa A/S (DK) - Pharmexa presents data from influenza program

Summary: Pharmexa-Epimmune, the U.S.-based subsidiary of Pharmexa A/S, presents selected data from its influenza vaccine program today at the Influenza Conference entitled, "Options for the Control of Influenza VI," held in Toronto, Ontario, Canada. The data show that a "universal" vaccine designe...

Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine

...with low royalty stacking. The Company has concluded deals with commercial organizations such as Peregrine, XOMA, NatImmune, Viventia, Dyax, Micromet, pharmexa and others. Further information at www.affitech.com. Contact Affitech (Norway) Dr. Martin Welschof Chief Executive Officer +47 22 95 87 58 <...

Pharmexa A/S (DK) - Long lasting immune response and survival to RAS vaccine

...f Executive Officer, telephone +45 4516 2525 Claude Mikkelsen, Head of Investor Relations, telephone +45 4516 2525 or +45 4060 2558 Note to editors: pharmexa A/S is a leading company in the field of active immunotherapy and vaccines for the treatment of cancer, serious chronic and infectious diseases. Pharm...

Pharmexa in Biological Technology

Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech

... Affitech A/S is an antibody research and development company. It was formed recently by a reverse merger of Norway, Oslo-based Affitech AS with pharmexa A/S, a Danish biotech company. The merged company has developed several proprietary technology platforms that constitute a highly productive, fully h...

Pharmexa and Affitech to Combine Operations to Create a New Antibody Therapeutics Company

... COPENHAGEN and OSLO, March 4 /PRNewswire/ -- pharmexa A/S and Affitech AS announced today that they have...anies by means of a share for share acquisition by pharmexa A/S of the private Norwegian company, Affitech AS. The purpose of the merger is to transform pharmexa from a cancer and infectious disease vaccine busin...

Affitech Acquires Pharmexa's Diabody Technology

...ndidates for a variety of therapeutic applications. The acquisition follows an exclusive license of the diabody IP that Affitech obtained in 2007 from pharmexa to carry out certain non-clinical GLP compliant studies, as well as sub-licensing arrangements with third parties. Affitech CEO Martin Welschof comm...

Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration

...y stacking. The Company has concluded deals with commercial organizations such as Omeros, Roche, Peregrine, XOMA, NatImmune, Viventia, Dyax, Micromet, pharmexa and others. Further information at http://www.affitech.com . Contacts for Affitech: Affitech (Norway): Dr. Martin Welschof Chief Executive Off...

Affitech Appoints Dr. Keith McCullagh as Chairman

...y stacking. The Company has concluded deals with commercial organizations such as Roche, Peregrine, Omeros, XOMA, NatImmune, Viventia, Dyax, Micromet, pharmexa and others. Further information at http://www.affitech.com . About Keith McCullagh Keith McCullagh, PhD, BVSc, MRCVS, is an experienced bioscienc...

Emergence of Cancer Vaccines Will Be the Key Factor Driving the Pancreatic Cancer Drug Market to More Than Double by 2016

...orld's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the emergence of cancer vaccines, including drugs from pharmexa and Cell Genesys, will be the key factor driving the pancreatic cancer drug market to more than double by 2016. The new Pharmacor report entitled Pan...